Skip to content
Sonic
AI
Sonic
AI
Home
Discover
Ask Sonic
Projects
Use with Claude or ChatGPT
Show me around
Request source or feature
From Blind Biopsies to Precision: Reinventing Medical Imaging with Reza Khorasaninejad, Founder ..., Sonic AI
Home
/
Outcomes Rocket
/
From Blind Biopsies to Precision: Reinventing Medical Imaging with Reza Khorasaninejad, Founder ...
Outcomes Rocket
Notify me
•
Jun 22, 2026
•
11:36
Interview
From Blind Biopsies to Precision: Reinventing Medical Imaging with Reza Khorasaninejad, Founder ...
From
Outcomes Rocket
Reza Khorasaninejad
(CEO and Founder, LeadOptic, guest)
Get the full transcript next time Outcomes Rocket releases an episode
Summary, key quotes, top claims, and the searchable transcript — emailed automatically. No card needed.
Sign up
Executive Summary
LeadOptic is commercializing a medical imaging device using proprietary metasurface technology to miniaturize optics and provide real-time guidance for lung cancer biopsies.
The technology addresses a significant clinical need, aiming to reduce the current 30% error rate in lung biopsies by increasing diagnostic accuracy from ~70% to over 90%.
The company has achieved key milestones, including FDA clearance, a 100% success rate in a 40-patient pilot study, and the conversion of its first pilot site into a paying customer.
LeadOptic is launching the RISE clinical study with Stanford Medicine to develop AI-based decision support models, building on its high-quality imaging hardware to further assist physicians.
Continue your research
Keep pulling the thread on Reza Khorasaninejad.
Miniaturization of Medical Imaging
Improving Diagnostic Accuracy in Oncology
12
quotes
Transcript
Key Arguments
Analysis
Quotes & Entities
12
Related
Loading transcript...
Processed Jun 24, 2026
Daily intelligence brief →
yt-dlp + mlx-whisper + Gemini